EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Persistent lineage plasticity driving lung cancer development and progression

Fanchen Meng, Jianyu Li, Zhijun Xia, Qinglin Wang, Qinhong Sun, Siwei Wang, Lin Xu iD, Rong Yin iD

Clinical and Translational Medicine · 2025-08 · 15 (8)

DOI: 10.1002/ctm2.70458 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Medicine, online erschienen am 22.08.2025. Verfasst von Fanchen Meng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics, Jiangsu Cancer Hospital & Nanjing Medical Unive…. Hauptthemen laut MEDLINE: Lung Neoplasms, Cell Lineage. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 255 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Foundation of China, Natural Science Foundation of Jiangsu Province, Jiangsu Cancer Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung cancer, a leading cause of cancer death, displays profound histologic and molecular heterogeneity across adenocarcinoma, squamous, and small‐cell types. Clinically, tumours can shift between these states, reflecting lineage plasticity—the reprogramming of differentiated cells to alternate identities. Pre‐existing genomic/epigenomic diversity and microenvironmental cues supply the substrates and pressures for plasticity from disease onset. This review anchors plasticity within normal lung development to clarify how fate programs are co‐opted to drive progression, immune escape, therapy resistance, and invasion. Main text Focusing on the intricate interplay between lineage dysregulation and tumour progression in lung cancer, this review integrates insights from lung tissue development to explore the pivotal molecules and mechanisms driving lineage plasticity, alterations and migration during lung carcinogenesis and progression. Recent research findings on lung cancer lineage plasticity are synthesised, shedding light on the role of transcriptional and epigenetic regulators in disrupting tumour lineages. Particular emphasis is placed on how tumour microenvironmental factors, such as hypoxia, stromal cells and immune cells, reshape tumour cellular profiles by modulating the epigenomic landscape. Furthermore, this review specifically discusses the impact of epidermal growth factor receptor ( EGFR) and KRAS mutations on lung cancer progression and the consequent immune escape mechanisms they engender. Importantly, we highlight that lineage regulation persists throughout tumour development, from the early onset of lung adenocarcinoma (LUAD) to its progression through late‐stage dedifferentiation and metastasis. We evaluate the implications of these factors on treatment resistance in lung cancer and focus on innovative therapeutic strategies targeting lineage plasticity.

Conclusions

Lineage plasticity spans the entire course of lung cancer, from early tumorigenesis through metastasis to treatment resistance. Lineage transitions that occur during tumour progression arise from specific combinations of genomic and epigenetic alterations and are further shaped by microenvironmental forces such as hypoxia, stromal remodeling, and immune pressure. By summarising current research advancements, we aim to provide new insights for future lung cancer research and to promote the development of more effective therapeutic interventions. Key points Lineage plasticity runs through the entire process of lung cancer progression and drug resistance, and drives early tumorigenesis via lineage imbalance. Certain driver mutations have lineage‐restricted tumorigenic potential, requiring lineage reprogramming for tumor initiation. Lineage transitions in lung cancer require specific genomic and epigenetic alterations. Lineage plasticity insights provide a mechanistic framework linking lung cancer origin, evolution, and therapeutic vulnerabilities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCell LineageHumansDisease ProgressionTumor Microenvironment

Stichwörter der Autor:innen

histopathologic transitionlineage imbalancelung cancerlung development

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics, Jiangsu Cancer Hospital & Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Institute of Cancer Researc…
  • Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
  • Department of Science and Technology, Jiangsu Cancer Hospital & Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China.
  • Biobank of Lung Cancer, Jiangsu Biobank of Clinical Resources, Nanjing, China.

ORCID-Profile: Lin Xu, Rong Yin

Förderung

  • National Science Foundation of China
  • Natural Science Foundation of Jiangsu Province
  • Jiangsu Cancer Hospital
  • National Natural Science Foundation of China

Zitieren

APA

Meng, F., Li, J., Xia, Z., Wang, Q., Sun, Q., Wang, S., Xu, L., & Yin, R. (2025). Persistent lineage plasticity driving lung cancer development and progression. Clinical and Translational Medicine, 15(8). https://doi.org/10.1002/ctm2.70458

Vancouver

Meng F, Li J, Xia Z, Wang Q, Sun Q, Wang S, et al. Persistent lineage plasticity driving lung cancer development and progression. Clinical and Translational Medicine. 2025;15(8). doi:10.1002/ctm2.70458

BibTeX
@article{Meng2025,
  author = {Meng, Fanchen and Li, Jianyu and Xia, Zhijun and Wang, Qinglin and Sun, Qinhong and Wang, Siwei and Xu, Lin and Yin, Rong},
  title = {Persistent lineage plasticity driving lung cancer development and progression},
  journal = {Clinical and Translational Medicine},
  year = {2025},
  volume = {15},
  number = {8},
  doi = {10.1002/ctm2.70458}
}
Kostenlos starten →